调强放疗IMRT同步卡培他滨化疗治疗直肠癌疗效评估  

Evaluation of the Effect of Intensity Modulated Radiotherapy IMRT Synchronous Capecitabine Chemotherapy for Rectal Cancer

作　　者：周芳[1] 陈亚楠[1] 钱晓兰[1] 徐丽贤[1] 梁素莹 ZHOU Fang CHEN Ya＇nan QIAN Xiaolan XU Lixian LIANG Suying(Department of Oncology, Zhang/iagang First People＇s Hospital, Zhangjiagang Jiangsu 215600, China)

机构地区：[1]江苏省张家港市第一人民医院肿瘤科,江苏张家港215600

出　　处：《中国继续医学教育》2017年第23期169-171,共3页China Continuing Medical Education

摘　　要：目的探讨调强放疗IMRI同步卡培他滨疗治疗直肠癌的临床疗效。方法选取我院2009年1月—2017年3月收治的直肠癌患者47例作为研究对象。将其分为实验组(调强放疗IMRT同步卡培他滨片)和对照组(三维适形放疗3DCRT同步卡培他滨),对比观察两组疗效及副反应。结果实验组皮肤黏膜症状12例(50.0%),消化道症状17例(70.83%),骨髓抑制7例(29.17%),不良反应发生率均低于对照组,差异具有统计学意义(P<0.05)。结论 IMRT同步卡培他滨化疗治疗直肠癌副反应小,易于耐受。Objective To investigate the clinical efficacy of intensity modulated radiation therapy （IMRI） synchronized eapecitabine in the treatment of rectal cancer. Methods A total of 47 patients with rectal cancer were enrolled in our hospital from January 2009 to March 2017. The patients were divided into two groups： the experimental group （IMRTsynchronized capecitabine） and the control group （3DCRTsynchronized capecitabine） reaction. Results The skin and mucous membrane symptoms of the experimental group were 12 cases （50.0%）, the digestive symptoms were 17 cases （70.83%）, and 7 cases of myelosuppression （29.17%）, the incidence rate was lower than that of the control group, the difference was statistically significant （P〈0.05）. Conelusion IMRT synchronous capecitabine chemotherapy for rectal cancer adverse reaction.

关 键 词：直肠癌 IMRT 卡培他滨 化疗 

分 类 号：R735[医药卫生—肿瘤]